What is your preferred second line therapy for an HCC patient who progressed after first line checkpoint inhibitor monotherapy?   

After progression on immunotherapy monotherapy, assuming the patient is still eligible for further therapy and VEGF inhibition, I will move to a VEGF TKI. While the data supports the use of lenvatinib or sorafenib in the front-line setting (REFLECT and SHARP trials), I will use one of these agents (...

This is a great question as the sequencing of treatment in HCC has drastically changed following the approval of atezolizumab/bevacizumab in the front line setting. For patients who have progressed on single agent immune checkpoint inhibitor in the front line setting, I would consider atezolizu...